Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DAPAGLIFLOZIN Cause Intentional product use issue? 398 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 398 reports of Intentional product use issue have been filed in association with DAPAGLIFLOZIN (QTERN). This represents 1.9% of all adverse event reports for DAPAGLIFLOZIN.

398
Reports of Intentional product use issue with DAPAGLIFLOZIN
1.9%
of all DAPAGLIFLOZIN reports
2
Deaths
87
Hospitalizations

How Dangerous Is Intentional product use issue From DAPAGLIFLOZIN?

Of the 398 reports, 2 (0.5%) resulted in death, 87 (21.9%) required hospitalization, and 80 (20.1%) were considered life-threatening.

Is Intentional product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DAPAGLIFLOZIN. However, 398 reports have been filed with the FAERS database.

What Other Side Effects Does DAPAGLIFLOZIN Cause?

Death (2,775) Diabetic ketoacidosis (1,773) Acute kidney injury (982) Off label use (891) Nausea (884) Dehydration (860) Vomiting (838) Dizziness (817) Ketoacidosis (803) Fatigue (785)

What Other Drugs Cause Intentional product use issue?

INFLIXIMAB (11,028) RITUXIMAB (9,602) INFLIXIMAB-DYYB (7,549) TOCILIZUMAB (5,078) METHOTREXATE (4,087) PREDNISONE (3,961) ABATACEPT (3,693) ADALIMUMAB (3,557) NIVOLUMAB (3,297) LEFLUNOMIDE (3,280)

Which DAPAGLIFLOZIN Alternatives Have Lower Intentional product use issue Risk?

DAPAGLIFLOZIN vs DAPAGLIFLOZIN PROPANEDIOL DAPAGLIFLOZIN vs DAPAGLIFLOZIN PROPANEDIOL\METFORMIN DAPAGLIFLOZIN vs DAPRODUSTAT DAPAGLIFLOZIN vs DAPSONE DAPAGLIFLOZIN vs DAPTOMYCIN

Related Pages

DAPAGLIFLOZIN Full Profile All Intentional product use issue Reports All Drugs Causing Intentional product use issue DAPAGLIFLOZIN Demographics